Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension

Hypertension

Volumn 44, Issue 3, 2004, Pages 300-304

  Hrafnkelsdóttir, Thórdís ^a   Ottosson, Pia ^a   Gudnason, Thorarinn ^a   Samuelsson, Ola ^a   Jern, Sverker ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Endothelium; Hypertension, essential; Hypertension, renal; Kidney failure; Tissue type plasminogen activator

Indexed keywords

DESMOPRESSIN; METHACHOLINE; NITROPRUSSIDE SODIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARM BLOOD FLOW; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; ESSENTIAL HYPERTENSION; FIBRINOLYSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MALE; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; THROMBOSIS; VASCULAR ENDOTHELIUM; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADULT; AGED; BRACHIAL ARTERY; DEAMINO ARGININE VASOPRESSIN; ENDOTHELIUM, VASCULAR; FOREARM; HUMANS; HYPERTENSION; HYPERTENSION, RENOVASCULAR; INFUSIONS, INTRA-ARTERIAL; KIDNEY DISEASES; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; NITROPRUSSIDE; PLETHYSMOGRAPHY; SECRETORY RATE; TISSUE PLASMINOGEN ACTIVATOR; VASODILATION;

EID: 4444317926     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000137380.91476.fb     Document Type: Article

References (32)

1. Emeis JJ. Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products. Ann N Y Acad Sci. 1992;667:249-258.
2. Giles AR, Nesheim ME, Herring SW, Hoogendoom H, Stump DC, Heldebrant CM. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemost. 1990;63:476-481.
3. Hrafnkelsdottir T, Wall U, Jern C, Jern S. Impaired capacity for endogenous fibrinolysis in essential hypertension. Lancet. 1998;352:1597-1598.
4. Sjogren LS, Doroudi R, Gan L, Jungersten L, Hrafnkelsdottir T, Jern S. Elevated intraluminal pressure inhibits vascular tissue plasminogen activator secretion and downregulates its gene expression. Hypertension. 2000;35:1002-1008.
5. London GM, Marchais SJ, Metivier F, Guerin AP. Cardiovascular risk in end-stage renal disease: vascular aspects. Nephrol Dial Transplant. 2000;15 Suppl 5:97-104.
6. Losowsky MS, Walls WD. Abnormalities of haemostasis in renal failure. J R Coll Physicians Lond. 1971;5:148-156.
7. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet. 1989;1:461-463.
8. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Abnormalities of endothelial function in patients with predialysis renal failure. Heart. 2000;83:205-209.
9. Von Kaulla KN, Von Kaulla E, Wasantapruck S, Marchioro TL, Starzl TE. Blood coagulation in uremic patients before and after hemodialysis and transplantation of the kidney. Arch Surg. 1966;92:184-191.
10. Edward N, Young DP, Macleod M. Fibrinolytic activity in plasma and urine in chronic renal disease. J Clin Pathol. 1964;17:365-368.
11. Gris JC, Branger B, Vecina F, al Sabadani B, Fourcade J, Schved JF. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int. 1994;46:807-813.
12. Brommer EJ, Schicht I, Wijngaards G, Verheijen JH, Rijken DC. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients. Thromb Haemost. 1984;52:311-314.
13. Nakayama M, Yamada K, Yamamoto Y, Yokoyama K, Nakano H, Kubo H, Shigematsu T, Kawaguchi Y, Sakai O. Vascular endothelial dysfunction in patients on regular dialysis treatment. Clin Nephrol. 1994;42:117-120.
14. de Boer A, Kluft C, Kroon JM, Kasper FJ, Schoemaker HC, Pruis J, Breimer DD, Soons PA, Emeis JJ, Cohen AF. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thromb Haemost. 1992;67:83-87.
15. Jern S, Selin L, Bergbrant A, Jern C. Release of tissue-type plasminogen activator in response to muscarinic receptor stimulation in human forearm. Thromb Haemost. 1994;72:588-594.
16. Hrafnkelsdottir T, Erlinge D, Jern S. Extracellular nucleotides ATP and UTP induce a marked acute release of tissue-type plasminogen activator in vivo in man. Thromb Haemost. 2001;85:875-881.
17. Jern C, Selin L, Jern S. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress. Thromb Haemost. 1994;72:285-291.
18. Wall U, Jern S, Tengborn L, Jern C. Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm. Blood. 1998;91:529-537.
19. Brink HS, Derkx FH, Boomsma F, Brommer EJ, Schalekamp MA. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus. Neth J Med. 1993;43:5-12.
20. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899-1911.
21. Stenvinkel P. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purif 2001;19:143-151.
22. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem. 1988;263:5797-5803.
23. Yamamoto C, Kaji T, Sakamoto M, Kozuka H. Modulation by endothelin-1 of tissue plasminogen activator and plasminogen activator inhibitor-1 release from cultured human vascular endothelial cells: interaction of endothelin-1 with cytokines. Biol Phann Bull. 1993;16:714-715.
24. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, Fox KA, Boon NA. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation. 2001;103:1936-1941.
25. Gudnason T, Hrafakelsdottir T, Wall U, Swedberg K, Jern S. Fibrinolytic capacity increases with age in healthy humans, while endothelium-dependent vasodilation is unaffected. Thromb Haemost. 2003;89:374-381.
26. Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, Imaizumi T. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation. 2000;101:1002-1006.
27. Cupisti A, Rossi M, Placidi S, Caprioli R, Morelli E, Vagheggini G, Barsotti G. Responses of the skin microcirculation to acetylcholine and to sodium nitroprusside in chronic uremic patients. Int J Clin Lab Res. 2000;30:157-162.
28. Thuraisingham RC, Raine AE. Maintenance of normal agonist-induced endothelium-dependent relaxation in uraemic and hypertensive resistance vessels. Nephrol Dial Transplant. 1999;14:70-75.
29. Annuk M, Lind L, Linde T, Fellstrom B. Impaired endothelium-dependent vasodilatation in renal failure in humans. Nephrol Dial Transplant. 2001;16:302-306.
30. DeSouza CA, Clevenger CM, Greiner JJ, Smith DT, Hoetzer GL, Shapiro LF, Stauffer BL. Evidence for agonist-specific endothelial vasodilator dysfunction with ageing in healthy humans. J Physiol. 2002;542:255-262.
31. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost. 1995;74:429-436.
32. Ladenvall P, Johansson L, Jansson JH, Jern S, Nilsson TK, Tjarnlund A, Jern C, Boman K. Tissue-type plasminogen activator -7.351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb Haemost. 2002;87:105-109.